Methylpyrrolopyrimidinecarboxami des

Abstract

The present invention relates to compound of formula (I) wherein R1 is -CH2-3-6C-cycloalkyl or 1-4C-alkyl which is optionally substituted by R11, R2 is hydrogen or 1 -4C-alkyl R21 is hydrogen or fluoro, R22 is hydrogen, halogen, 1 -4C-alkyl, 1 -4C-alkoxy, hydroxy, 1-4C-fluoroalkoxy, - C(O)-I -4C- alkyl or 1-4C-fluoroalkyl, or R21 and R22 combine to form a group -0-CH2-O-, R23 is hydrogen, halogen, 1-4C-alkyl, 1 -4C-alkoxy, hydroxy or 1 -4C-fluoroaikoxy, or R22 and R23 combine to form a group -0-CH2-O-, R24 is hydrogen, Y is -(CH2)n-, R3 is a 4- to 7-membered saturated heterocyclic ring containing one nitrogen atom and optionally one oxygen atom, said heterocyclic ring being optionally substituted by R4 and / or by one or two substituents R5, or a 3-6C-cycloalkyl group substituted by R6 and optionally substituted by R61, The stereoisomer of the compound is effective inhibitor of the type 5 phosphodiesterase. The invention relates to methylpyrrolopyrimidinecarboxamide compound, process for its preparation, pharmaceutical composition comprising said compound, for use in the treatment or prophylaxis of diseases.